Conference
A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1 st -line docetaxel therapy
Authors
Saad F; Hotte SJ; North SA; Eigl BJ; Chi KN; Czaykowski P; Polllak M; Wood L; Winquist E
Volume
26
Pagination
pp. 5002-5002
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2008
DOI
10.1200/jco.2008.26.15_suppl.5002
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X